Logan Capital Management Inc. Sells 27,302 Shares of Zoetis Inc. $ZTS

Logan Capital Management Inc. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 35.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 50,175 shares of the company’s stock after selling 27,302 shares during the quarter. Logan Capital Management Inc.’s holdings in Zoetis were worth $6,313,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Global Wealth Strategies & Associates bought a new position in Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis during the third quarter worth about $31,000. Holos Integrated Wealth LLC bought a new position in Zoetis during the fourth quarter worth about $32,000. Finally, Elyxium Wealth LLC bought a new position in Zoetis during the fourth quarter worth about $32,000. 92.80% of the stock is owned by institutional investors.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Insider Activity

In related news, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $81.51 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $168.83. The firm has a market cap of $34.17 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.27 and a beta of 0.75. The company’s 50-day moving average price is $97.70 and its two-hundred day moving average price is $114.47.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the business earned $1.48 earnings per share. Zoetis’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ZTS. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Bank of America raised their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Finally, UBS Group decreased their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.